Investigators compared RNA sequence data in heart samples from individuals with dilated cardiomyopathy and samples from healthy transplant donor hearts.
After six months of follow up, the costs of additional tests and consultations in the group receiving whole-genome sequencing were not significantly higher than in the control group.
Harvard researchers found that variants previously classified as pathogenic were in fact benign, disproportionately affecting patients of African ancestry.
Last week, the firm launched AtheroGxOne the second of two cardiovascular next-gen sequencing panels, and hopes to launch its first liquid biopsy test in 2017.
With the funding, OSU researchers will conduct cardiovascular phenotyping and exome sequencing of DCM patients of European, African, and Hispanic ancestry.
The panel profiles more than 100 genes associated with inherited heart conditions, and may enable more efficient, cost-effective identification of causal mutations.
